[1] 中华医学会肝病学分会, 中华医学会传染病与寄生虫病学分会. 丙型肝炎防治指南. 中华肝脏病杂志,2004, 12:194-198.
[2] 刘胜林. 丙肝病毒核心抗原的检测在诊断丙肝中的意义. 继续医学教育, 2014, 28:44-46.
[3] Ciesek S, Steinmann E, Wedemeyer H, et al. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology, 2009, 50:1638-1645.
[4] 买制刚. 丙型肝炎临床检验技术现状与发展. 中国卫生检验杂志, 2008, 18:190-192.
[5] 周永兴, 贾战生. 进一步加强病毒性肝炎基因治疗的研究. 第四军医大学学报, 2000, 21:781-783.
[6] 尹秀华. 丙型肝炎检测方法的研究进展.医学理论与实践, 2013, 26:171-173.
[7] 廖冰洁,周迎春,谢在春,等. 几种丙肝抗体检测的临床应用评价. 现代检验医学杂志, 2012,27:106-108.
[8] 徐东平, 陈国凤. 丙型肝炎基因治疗研究进展. 中华实验和临床感染病杂志. 2009, 3:338-342.
[9] Lemon SM, McKeating JA, Pietschmann T, et al. Development of novel therapies for hepatitis C. Antiviral Res, 2010, 86:79-92.
[10] Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 1999, 285:110-113.
[11] Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science, 2003, 301:1884-1886.
[12] Georganopoulou DG, Chang L, Nam JM, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer′s disease. Proc Natl Acad Sci U S A, 2005, 102:2273-2276.
[13] 陈青根,黄丽华. ELISA 法检测丙肝抗体原理及影响因素分析. 健康大视野, 2012, 20:372-373.
[14] 毛远丽,王晗,李伯安. HCV 实验室检测方法与临床应用. 传染病信息, 2012, 25:75-79. |
